CClinicalTrials.gg
Status unknownNCT03480503Updated Mar 29, 2018

Apelin12 in Acne Vulgaris

An observational study in Acne Vulgaris, sponsored by Assiut University. Status unknown. Per ClinicalTrials.gov, last updated 2018-03-29.

Sponsored by Assiut University · Observational

The sponsor has not verified this record recently (last verified Mar 2018), so the status shown — last known as Not yet recruiting — may be out of date.
Study type
Observational
Model
Case-control
Time perspective
Retrospective
Enrollment
90
Sex
All
01

Study summary

Acne vulgaris is a common chronic inflammatory disease of the pilosebaceous unit which is characterized by the formation of non-inflammatory open and closed comedones and inflammatory papules, pustules, nodules and cysts.

It is a multifactorial disease that affects mostly adolescent population. Acne appears very early in puberty during the preteen years, often before menarche in girls. Because many adolescents have acne, it is difficult to predict which individuals are prone to severe cases.

The pathogenesis of acne is complex, with strong evidence supporting the involvement of follicular hyperkeratinization, hyperactivity of the sebaceous glands, colonization of Propionibacterium acnes and yeast, and inflammation. Although the importance of androgens in the pathophysiology of acne has been supported by both clinical studies and experimental data, the research evaluating adipokines are very few in patients with acne vulgaris.

Read the detailed description

Acne lesions may vary in number during the natural course of the disease and multiple measurements have been developed which is based on clinical examination and photographic documentation, to measure the clinical severity.

The Grading of acne based on the type of lesions, affected surface area and their severity that can help in deciding which therapies are needed in each individual. However, no grading system has been accepted universally. The Global Acne Grading System is a quantitative scoring system to assess the severity of acne. According to this score acne was graded as mild, moderate, severe and very severe.

The severity of acne was also graded using the Comprehensive Acne Severity Scale.

Adipokines are proteins that are synthesized and secreted primarily by adipocytes in response to various stimuli, include interleukin 6 and other small molecular weight bioactive proteins such as adiponectin, resistin, leptin, serpin E1 [also known as plasminogen activator inhibitor 1 and endothelial plasminogen activator inhibitor], visfatin (also known as nicotinamide phosphoribosyltransferase), apelin, chemerin, retinol binding protein 4, and monocyte chemoattractant protein 1.

Due to their different biological properties and diverse cellular targets adipokines are involved in a wide array of (patho)physiological processes and are responsible for mediating the inflammatory effects of the adipose tissue in the local tissue environment as well as to different organs via circulation. By detecting alterations in their serum levels also in dermatological diseases such as acne vulgaris and psoriasis, extensive studies have also started in dermatological research to identify the possible targets and the cutaneous sources of these proteins.

Apelin is an endogenous ligand of the previously discovered "orphan" receptor named APJ, isolated from bovine stomach extracts.

It is a product of apelin gene that is located on chromosome Xq25-26.1 and translated as a 77 amino acid prepropeptide. It is processed into several active molecular forms with different biological activities. Apelin belongs to adipokines group because its m-RNA expression has been demonstrated in mature adipocytes in rodents and humans.

Apelin peptide expression has been also demonstrated in several tissues and seems to have different regulatory functions, depending on the expressing tissue, the apelinergic system distribution over such a variety of tissues has suggested that it might play relevant roles in human physiology.

Apelin has been reported to have an effect on appetite, drinking behavior, angiogenesis, and the cardiovascular system. It is regulated by insulin. Apelin might be a novel target for preventing obesity and obesity-related diseases via enhancement of vascular integrity.

Several active apelin forms exist such as apelin-36, apelin-17, apelin-13, and apelin-12.

Apelin-12 is a 12-amino peptide fragment that has been implicated in reducing blood pressure via a nitric oxide mechanism, and is involved in feeding mechanisms via stimulation of cholecystokinin secretion.

It is considered to be one of the most potent isoform of apelin.

The studies evaluating the role of adipokines are very few in patient with acne vulgaris.

02

Conditions studied

  • Acne Vulgaris

Browse trials for

Keywords

  • Apelin12
03

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

The study will be performed at Department of Dermatology, Venereology and Andrology in Assiut University Hospital.

Inclusion criteria

  • Acne vulgaris patients from different ages and sex.

Exclusion criteria

Exclusion Criteria:

  • Pregnant and lactating females.
  • Local cutaneous infection or any other dermatological diseases.
  • Diabetic patients or severe systemic disease such as liver and renal failure.
04

Study design

Observational model
Case-control
Time perspective
Retrospective
Enrollment
90 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • study group

    Patients with acne vulgaris , measurement of serum apelin12 by using ELISA technique ,complete lipid profile and fasting blood glucose.

  • Control group

    Healthy control volunteers, measurement of serum apelin12 by using ELISA technique ,complete lipid profile and fasting blood glucose.

05

What researchers measure

Primary outcomes

  1. serum apelin12

    blood samples will be taken then measurement of serum apelin12 by using ELISA technique after fasting 12 hours.

    Time frame: 12 hour

Secondary outcomes

  1. Complete lipid profile.

    blood samples will be taken and complete lipid profile will be measured after fasting 12 hours by biochemical measurement.

    Time frame: 12hour

  2. Fasting blood glucose

    blood samples will be taken and fasting blood glucose level will be measured after fasting 7 hours by biochemical measurement method.

    Time frame: 7hours

06

Study locations

No study locations are listed for this record.

07

References and documents

Publications

  • Boucher J, Masri B, Daviaud D, Gesta S, Guigne C, Mazzucotelli A, Castan-Laurell I, Tack I, Knibiehler B, Carpene C, Audigier Y, Saulnier-Blache JS, Valet P. Apelin, a newly identified adipokine up-regulated by insulin and obesity. Endocrinology. 2005 Apr;146(4):1764-71. doi: 10.1210/en.2004-1427. Epub 2005 Jan 27. PubMed 15677759 ↗
  • Carpene C, Dray C, Attane C, Valet P, Portillo MP, Churruca I, Milagro FI, Castan-Laurell I. Expanding role for the apelin/APJ system in physiopathology. J Physiol Biochem. 2007 Dec;63(4):359-73. PubMed 18457011 ↗
  • Cordain L, Lindeberg S, Hurtado M, Hill K, Eaton SB, Brand-Miller J. Acne vulgaris: a disease of Western civilization. Arch Dermatol. 2002 Dec;138(12):1584-90. doi: 10.1001/archderm.138.12.1584. PubMed 12472346 ↗
  • Cox CM, D'Agostino SL, Miller MK, Heimark RL, Krieg PA. Apelin, the ligand for the endothelial G-protein-coupled receptor, APJ, is a potent angiogenic factor required for normal vascular development of the frog embryo. Dev Biol. 2006 Aug 1;296(1):177-89. doi: 10.1016/j.ydbio.2006.04.452. Epub 2006 Apr 27. PubMed 16750822 ↗
  • De Falco M, De Luca L, Onori N, Cavallotti I, Artigiano F, Esposito V, De Luca B, Laforgia V, Groeger AM, De Luca A. Apelin expression in normal human tissues. In Vivo. 2002 Sep-Oct;16(5):333-6. PubMed 12494873 ↗
  • Doshi A, Zaheer A, Stiller MJ. A comparison of current acne grading systems and proposal of a novel system. Int J Dermatol. 1997 Jun;36(6):416-8. doi: 10.1046/j.1365-4362.1997.00099.x. No abstract available. PubMed 9248884 ↗
  • Farkasfalvi K, Stagg MA, Coppen SR, Siedlecka U, Lee J, Soppa GK, Marczin N, Szokodi I, Yacoub MH, Terracciano CM. Direct effects of apelin on cardiomyocyte contractility and electrophysiology. Biochem Biophys Res Commun. 2007 Jun 15;357(4):889-95. doi: 10.1016/j.bbrc.2007.04.017. Epub 2007 Apr 12. PubMed 17466269 ↗
  • Gerdes S, Rostami-Yazdi M, Mrowietz U. Adipokines and psoriasis. Exp Dermatol. 2011 Feb;20(2):81-7. doi: 10.1111/j.1600-0625.2010.01210.x. PubMed 21255085 ↗
  • Kawamata Y, Habata Y, Fukusumi S, Hosoya M, Fujii R, Hinuma S, Nishizawa N, Kitada C, Onda H, Nishimura O, Fujino M. Molecular properties of apelin: tissue distribution and receptor binding. Biochim Biophys Acta. 2001 Apr 23;1538(2-3):162-71. doi: 10.1016/s0167-4889(00)00143-9. PubMed 11336787 ↗
  • Kitabchi AE, Imseis RE, Bush AJ, Williams-Cleaves B, Pourmotabbed G. Racial differences in the correlation between gonadal androgens and serum insulin levels. Diabetes Care. 1999 Sep;22(9):1524-9. doi: 10.2337/diacare.22.9.1524. PubMed 10480520 ↗
  • Lee DK, Cheng R, Nguyen T, Fan T, Kariyawasam AP, Liu Y, Osmond DH, George SR, O'Dowd BF. Characterization of apelin, the ligand for the APJ receptor. J Neurochem. 2000 Jan;74(1):34-41. doi: 10.1046/j.1471-4159.2000.0740034.x. PubMed 10617103 ↗
  • Lehmann HP, Robinson KA, Andrews JS, Holloway V, Goodman SN. Acne therapy: a methodologic review. J Am Acad Dermatol. 2002 Aug;47(2):231-40. doi: 10.1067/mjd.2002.120912. PubMed 12140469 ↗
  • Liang T, Hoyer S, Yu R, Soltani K, Lorincz AL, Hiipakka RA, Liao S. Immunocytochemical localization of androgen receptors in human skin using monoclonal antibodies against the androgen receptor. J Invest Dermatol. 1993 May;100(5):663-6. doi: 10.1111/1523-1747.ep12472330. PubMed 7684056 ↗
  • Mesmin C, Fenaille F, Becher F, Tabet JC, Ezan E. Identification and characterization of apelin peptides in bovine colostrum and milk by liquid chromatography-mass spectrometry. J Proteome Res. 2011 Nov 4;10(11):5222-31. doi: 10.1021/pr200725x. Epub 2011 Oct 13. PubMed 21939284 ↗
  • Najafipour H, Soltani Hekmat A, Nekooian AA, Esmaeili-Mahani S. Apelin receptor expression in ischemic and non- ischemic kidneys and cardiovascular responses to apelin in chronic two-kidney-one-clip hypertension in rats. Regul Pept. 2012 Oct 10;178(1-3):43-50. doi: 10.1016/j.regpep.2012.06.006. Epub 2012 Jul 14. PubMed 22796316 ↗
  • Ohno S, Yakabi K, Ro S, Ochiai M, Onouchi T, Sakurada T, Takabayashi H, Ishida S, Takayama K. Apelin-12 stimulates acid secretion through an increase of histamine release in rat stomachs. Regul Pept. 2012 Feb 10;174(1-3):71-8. doi: 10.1016/j.regpep.2011.12.002. Epub 2011 Dec 28. PubMed 22209991 ↗
  • Ozuguz P, Kacar SD, Asik G, Ozuguz U, Karatas S. Evaluation of leptin, adiponectin, and ghrelin levels in patients with acne vulgaris. Hum Exp Toxicol. 2017 Jan;36(1):3-7. doi: 10.1177/0960327116630355. Epub 2016 Jul 11. PubMed 26860691 ↗
  • Sawane M, Kajiya K, Kidoya H, Takagi M, Muramatsu F, Takakura N. Apelin inhibits diet-induced obesity by enhancing lymphatic and blood vessel integrity. Diabetes. 2013 Jun;62(6):1970-80. doi: 10.2337/db12-0604. Epub 2013 Feb 1. PubMed 23378608 ↗
  • Seleit I, Bakry OA, Abdou AG, Hashim A. Body mass index, selected dietary factors, and acne severity: are they related to in situ expression of insulin-like growth factor-1? Anal Quant Cytopathol Histpathol. 2014 Oct;36(5):267-78. PubMed 25803999 ↗
  • Strauss JS, Krowchuk DP, Leyden JJ, Lucky AW, Shalita AR, Siegfried EC, Thiboutot DM, Van Voorhees AS, Beutner KA, Sieck CK, Bhushan R; American Academy of Dermatology/American Academy of Dermatology Association. Guidelines of care for acne vulgaris management. J Am Acad Dermatol. 2007 Apr;56(4):651-63. doi: 10.1016/j.jaad.2006.08.048. Epub 2007 Feb 5. PubMed 17276540 ↗
  • Sunter D, Hewson AK, Dickson SL. Intracerebroventricular injection of apelin-13 reduces food intake in the rat. Neurosci Lett. 2003 Dec 15;353(1):1-4. doi: 10.1016/s0304-3940(03)00351-3. PubMed 14642423 ↗
  • Tatemoto K, Hosoya M, Habata Y, Fujii R, Kakegawa T, Zou MX, Kawamata Y, Fukusumi S, Hinuma S, Kitada C, Kurokawa T, Onda H, Fujino M. Isolation and characterization of a novel endogenous peptide ligand for the human APJ receptor. Biochem Biophys Res Commun. 1998 Oct 20;251(2):471-6. doi: 10.1006/bbrc.1998.9489. PubMed 9792798 ↗
  • Tatemoto K, Takayama K, Zou MX, Kumaki I, Zhang W, Kumano K, Fujimiya M. The novel peptide apelin lowers blood pressure via a nitric oxide-dependent mechanism. Regul Pept. 2001 Jun 15;99(2-3):87-92. doi: 10.1016/s0167-0115(01)00236-1. PubMed 11384769 ↗
  • Thiboutot D, Gollnick H, Bettoli V, Dreno B, Kang S, Leyden JJ, Shalita AR, Lozada VT, Berson D, Finlay A, Goh CL, Herane MI, Kaminsky A, Kubba R, Layton A, Miyachi Y, Perez M, Martin JP, Ramos-E-Silva M, See JA, Shear N, Wolf J Jr; Global Alliance to Improve Outcomes in Acne. New insights into the management of acne: an update from the Global Alliance to Improve Outcomes in Acne group. J Am Acad Dermatol. 2009 May;60(5 Suppl):S1-50. doi: 10.1016/j.jaad.2009.01.019. PubMed 19376456 ↗
  • Trayhurn P, Wang B, Wood IS. Hypoxia in adipose tissue: a basis for the dysregulation of tissue function in obesity? Br J Nutr. 2008 Aug;100(2):227-35. doi: 10.1017/S0007114508971282. Epub 2008 Apr 9. PubMed 18397542 ↗
  • Witkowski JA, Parish LC. The assessment of acne: an evaluation of grading and lesion counting in the measurement of acne. Clin Dermatol. 2004 Sep-Oct;22(5):394-7. doi: 10.1016/j.clindermatol.2004.03.008. PubMed 15556725 ↗

Individual participant data

Plan to share: Undecided

08

Registry details

Key details

Study ID
NCT03480503
Lead sponsor
Assiut University
Responsible party
Amira Abdelaziz (Principal Investigator, Assiut University) — Principal investigator
First posted
Mar 29, 2018
Start date
May 2018 (estimated)
Primary completion
Oct 2019 (estimated)
Completion
Dec 2019 (estimated)
Last update
Mar 29, 2018

Study contacts

Doaa Abu taleb, lecturer
Contact
Dodda_aboutaleb@yahoo.com
01001463937
Eman Kamal, assis prof
Contact
emohanya@yahoo.com
01005369338

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Mar 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion